241 related articles for article (PubMed ID: 2535725)
1. Posttranslational modifications distinguish the envelope glycoprotein of the immunodeficiency disease-inducing feline leukemia virus retrovirus.
Poss ML; Mullins JI; Hoover EA
J Virol; 1989 Jan; 63(1):189-95. PubMed ID: 2535725
[TBL] [Abstract][Full Text] [Related]
2. Characterization and significance of delayed processing of the feline leukemia virus FeLV-FAIDS envelope glycoprotein.
Poss ML; Quackenbush SL; Mullins JI; Hoover EA
J Virol; 1990 Sep; 64(9):4338-45. PubMed ID: 2166820
[TBL] [Abstract][Full Text] [Related]
3. Distinct superinfection interference properties yet similar receptor utilization by cytopathic and noncytopathic feline leukemia viruses.
Reinhart TA; Ghosh AK; Hoover EA; Mullins JI
J Virol; 1993 Sep; 67(9):5153-62. PubMed ID: 8394443
[TBL] [Abstract][Full Text] [Related]
4. Viral genetic determinants of T-cell killing and immunodeficiency disease induction by the feline leukemia virus FeLV-FAIDS.
Donahue PR; Quackenbush SL; Gallo MV; deNoronha CM; Overbaugh J; Hoover EA; Mullins JI
J Virol; 1991 Aug; 65(8):4461-9. PubMed ID: 1649341
[TBL] [Abstract][Full Text] [Related]
5. In vivo evolution of a novel, syncytium-inducing and cytopathic feline leukemia virus variant.
Rohn JL; Moser MS; Gwynn SR; Baldwin DN; Overbaugh J
J Virol; 1998 Apr; 72(4):2686-96. PubMed ID: 9525586
[TBL] [Abstract][Full Text] [Related]
6. Lymphocyte subset alterations and viral determinants of immunodeficiency disease induction by the feline leukemia virus FeLV-FAIDS.
Quackenbush SL; Donahue PR; Dean GA; Myles MH; Ackley CD; Cooper MD; Mullins JI; Hoover EA
J Virol; 1990 Nov; 64(11):5465-74. PubMed ID: 1976822
[TBL] [Abstract][Full Text] [Related]
7. The host range and interference properties of two closely related feline leukemia variants suggest that they use distinct receptors.
Moser M; Burns CC; Boomer S; Overbaugh J
Virology; 1998 Mar; 242(2):366-77. PubMed ID: 9514965
[TBL] [Abstract][Full Text] [Related]
8. Feline leukemia virus envelope sequences that affect T-cell tropism and syncytium formation are not part of known receptor-binding domains.
Gwynn SR; Hankenson FC; Lauring AS; Rohn JL; Overbaugh J
J Virol; 2000 Jul; 74(13):5754-61. PubMed ID: 10846053
[TBL] [Abstract][Full Text] [Related]
9. Delayed cytopathicity of a feline leukemia virus variant is due to four mutations in the transmembrane protein gene.
Thomas E; Overbaugh J
J Virol; 1993 Oct; 67(10):5724-32. PubMed ID: 8396654
[TBL] [Abstract][Full Text] [Related]
10. Structure and pathogenicity of individual variants within an immunodeficiency disease-inducing isolate of FeLV.
Overbaugh J; Hoover EA; Mullins JI; Burns DP; Rudensey L; Quackenbush SL; Stallard V; Donahue PR
Virology; 1992 Jun; 188(2):558-69. PubMed ID: 1316674
[TBL] [Abstract][Full Text] [Related]
11. Replication kinetics and cell tropism of an immunosuppressive feline leukaemia virus.
Quackenbush SL; Mullins JI; Hoover EA
J Gen Virol; 1996 Jul; 77 ( Pt 7)():1411-20. PubMed ID: 8757981
[TBL] [Abstract][Full Text] [Related]
12. Strong sequence conservation among horizontally transmissible, minimally pathogenic feline leukemia viruses.
Donahue PR; Hoover EA; Beltz GA; Riedel N; Hirsch VM; Overbaugh J; Mullins JI
J Virol; 1988 Mar; 62(3):722-31. PubMed ID: 2828667
[TBL] [Abstract][Full Text] [Related]
13. Molecular analysis and pathogenesis of the feline aplastic anemia retrovirus, feline leukemia virus C-Sarma.
Riedel N; Hoover EA; Gasper PW; Nicolson MO; Mullins JI
J Virol; 1986 Oct; 60(1):242-50. PubMed ID: 3018287
[TBL] [Abstract][Full Text] [Related]
14. Identification of a putative receptor for subgroup A feline leukemia virus on feline T cells.
Ghosh AK; Bachmann MH; Hoover EA; Mullins JI
J Virol; 1992 Jun; 66(6):3707-14. PubMed ID: 1316477
[TBL] [Abstract][Full Text] [Related]
15. Mutations within a putative cysteine loop of the transmembrane protein of an attenuated immunodeficiency-inducing feline leukemia virus variant inhibit envelope protein processing.
Burns CC; Poss ML; Thomas E; Overbaugh J
J Virol; 1995 Apr; 69(4):2126-32. PubMed ID: 7884859
[TBL] [Abstract][Full Text] [Related]
16. Induction of feline leukaemia virus-neutralizing antibodies by immunization with synthetic peptides derived from the FeLV env gene.
Weijer K; Pfauth A; van Herwijnen R; Jarrett O; Meloen RH; Tomee C; Osterhaus AD
Vaccine; 1993; 11(9):946-56. PubMed ID: 7692683
[TBL] [Abstract][Full Text] [Related]
17. Interference with superinfection and with cell killing and determination of host range and growth kinetics mediated by feline leukemia virus surface glycoproteins.
Kristal BS; Reinhart TA; Hoover EA; Mullins JI
J Virol; 1993 Jul; 67(7):4142-53. PubMed ID: 8389921
[TBL] [Abstract][Full Text] [Related]
18. Protection against feline leukemia virus infection by use of an inactivated virus vaccine.
Hoover EA; Perigo NA; Quackenbush SL; Mathiason-DuBard CK; Overbaugh JM; Kloetzer WS; Elder JH; Mullins JI
J Am Vet Med Assoc; 1991 Nov; 199(10):1392-401. PubMed ID: 1666090
[TBL] [Abstract][Full Text] [Related]
19. The surface glycoprotein of feline leukemia virus isolate FeLV-945 is a determinant of altered pathogenesis in the presence or absence of the unique viral long terminal repeat.
Bolin LL; Ahmad S; Lobelle-Rich PA; Ooms TG; Alvarez-Hernandez X; Didier PJ; Levy LS
J Virol; 2013 Oct; 87(19):10874-83. PubMed ID: 23903838
[TBL] [Abstract][Full Text] [Related]
20. Subtle mutational changes in the SU protein of a natural feline leukemia virus subgroup A isolate alter disease spectrum.
Chandhasin C; Coan PN; Levy LS
J Virol; 2005 Feb; 79(3):1351-60. PubMed ID: 15650161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
